COR2ED develops high-quality Medical Education programmes to help healthcare professionals improve the health of patients globally.

Update From AACR-NCI-EORTC: PYNNACLE phase 2 study
6:27
Update From AACR-NCI-EORTC: PYNNACLE phase 2 study
Bladder cancer highlights from ESMO 2025
4:25
Bladder cancer highlights from ESMO 2025
Breast cancer highlights from ESMO 2025
4:52
Breast cancer highlights from ESMO 2025
Gynecological cancer highlights from ESMO 2025
5:31
Gynecological cancer highlights from ESMO 2025
Advanced RCC Update from ESMO 2025
6:07
Advanced RCC Update from ESMO 2025
Oncogene-addicted non-small cell lung cancer highlights from ESMO 2025
5:12
Oncogene-addicted non-small cell lung cancer highlights from ESMO 2025
Upper GI cancer highlights from ESMO 2025
1:52
Upper GI cancer highlights from ESMO 2025
Highlights from ESMO 2025
0:55
Highlights from ESMO 2025
Highlights - Exploring the role of targeted radiopharmaceutical treatment in NETs
5:50
Highlights - Exploring the role of targeted radiopharmaceutical treatment in NETs
Exploring the role of targeted radiopharmaceutical treatment in NETs
21:57
Exploring the role of targeted radiopharmaceutical treatment in NETs
Highlights Part-2: Shared decision-making for prostate cancer patients
4:43
Highlights Part-2: Shared decision-making for prostate cancer patients
Shared decision-making for prostate cancer patients
27:22
Shared decision-making for prostate cancer patients
Highlights Part-1: Shared decision-making for prostate cancer patients
5:34
Highlights Part-1: Shared decision-making for prostate cancer patients
Oncogene-addicted NSCLC
5:48
Oncogene-addicted NSCLC
Improving acne vulgaris with multimodal treatment strategies
4:02
Improving acne vulgaris with multimodal treatment strategies
Managing ADC toxicities in HER2+ metastatic breast cancer
6:40
Managing ADC toxicities in HER2+ metastatic breast cancer
NTRK fusion testing and treatment in pediatric sarcoma
6:20
NTRK fusion testing and treatment in pediatric sarcoma
Later line treatment strategies in mCRC: switching vs rechallenge
10:28
Later line treatment strategies in mCRC: switching vs rechallenge
Innovating relapsed refractory multiple myeloma care: Streamlining therapy management
3:18
Innovating relapsed refractory multiple myeloma care: Streamlining therapy management
Innovating relapsed refractory multiple myeloma care: Addressing unmet needs
5:14
Innovating relapsed refractory multiple myeloma care: Addressing unmet needs
Innovating relapsed refractory multiple myeloma care: Real-world insights
3:01
Innovating relapsed refractory multiple myeloma care: Real-world insights
Optimising novel therapy sequencing from early relapse in multiple myeloma: Prof Evangelos Terpos
1:49
Optimising novel therapy sequencing from early relapse in multiple myeloma: Prof Evangelos Terpos
Advanced HCC: treatment strategies for patients ineligible for IO or those with progression on IO
3:22
Advanced HCC: treatment strategies for patients ineligible for IO or those with progression on IO
The evolution of our understanding that led us to rethink hypophosphatasia (HPP)
2:07
The evolution of our understanding that led us to rethink hypophosphatasia (HPP)
Recognising hypophosphatasia (HPP)
2:29
Recognising hypophosphatasia (HPP)
Prostate cancer update from ASCO 2025
5:04
Prostate cancer update from ASCO 2025
Lung cancer update from ASCO 2025
4:03
Lung cancer update from ASCO 2025
Gynecological cancer update from ASCO 2025
5:18
Gynecological cancer update from ASCO 2025
Breast cancer update from ASCO 2025
3:20
Breast cancer update from ASCO 2025
GI cancer update from ASCO 2025
5:37
GI cancer update from ASCO 2025